ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 173 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2019. The put-call ratio across all filers is 6.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,353,457 | -22.9% | 430,672 | -0.2% | 0.01% | -28.6% |
| Q2 2023 | $19,913,860 | +109909.2% | 431,690 | -4.4% | 0.01% | 0.0% |
| Q1 2023 | $18,102 | -15.9% | 451,418 | -2.8% | 0.01% | -12.5% |
| Q4 2022 | $21,514 | -99.7% | 464,369 | +127.5% | 0.01% | +166.7% |
| Q3 2022 | $8,454,000 | -29.2% | 204,157 | +1.9% | 0.00% | -40.0% |
| Q2 2022 | $11,949,000 | -32.7% | 200,283 | -22.4% | 0.01% | -16.7% |
| Q1 2022 | $17,755,000 | -17.7% | 258,145 | +0.7% | 0.01% | 0.0% |
| Q4 2021 | $21,565,000 | -20.4% | 256,455 | -14.7% | 0.01% | -25.0% |
| Q3 2021 | $27,104,000 | -0.9% | 300,525 | +4.7% | 0.01% | 0.0% |
| Q2 2021 | $27,361,000 | -35.0% | 286,957 | -22.4% | 0.01% | -38.5% |
| Q1 2021 | $42,086,000 | -23.7% | 369,632 | -7.2% | 0.01% | -31.6% |
| Q4 2020 | $55,153,000 | +74.6% | 398,423 | +3.6% | 0.02% | +58.3% |
| Q3 2020 | $31,594,000 | -7.1% | 384,406 | -11.5% | 0.01% | -14.3% |
| Q2 2020 | $33,992,000 | +131.1% | 434,563 | +31.3% | 0.01% | +100.0% |
| Q1 2020 | $14,710,000 | +13.8% | 331,091 | +9.4% | 0.01% | +40.0% |
| Q4 2019 | $12,931,000 | +10.6% | 302,769 | +10.7% | 0.01% | 0.0% |
| Q3 2019 | $11,695,000 | -33.0% | 273,386 | -0.6% | 0.01% | -28.6% |
| Q2 2019 | $17,467,000 | +5703.0% | 275,081 | +6239.7% | 0.01% | +250.0% |
| Q1 2019 | $301,000 | -75.1% | 4,339 | -77.7% | 0.00% | -75.0% |
| Q2 2017 | $1,207,000 | +57.0% | 19,439 | +71.3% | 0.01% | +60.0% |
| Q1 2017 | $769,000 | -25.7% | 11,349 | -22.9% | 0.01% | 0.0% |
| Q4 2016 | $1,035,000 | -29.8% | 14,717 | -29.2% | 0.01% | -44.4% |
| Q3 2016 | $1,474,000 | +32.9% | 20,783 | -8.4% | 0.01% | +28.6% |
| Q2 2016 | $1,109,000 | +1.0% | 22,679 | +30.7% | 0.01% | +16.7% |
| Q1 2016 | $1,098,000 | -52.4% | 17,348 | -15.7% | 0.01% | -50.0% |
| Q4 2015 | $2,308,000 | +10.4% | 20,581 | -5.2% | 0.01% | 0.0% |
| Q3 2015 | $2,091,000 | -3.5% | 21,714 | +2.6% | 0.01% | 0.0% |
| Q2 2015 | $2,166,000 | – | 21,160 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |